• Brain injuries affect all aspects of society, from recreational youth athletics to military trauma interventions
• Despite the commonality of brain concussion injuries — more than 5 million a year in the United States alone — no FDA-approved therapy exists
• Medical technology innovator Odyssey Health Inc. is working toward a commercialized product treatment solution to the unmet need of concussion injuries
• Odyssey’s product for treating brain concussion has recently completed a series of human and animal safety trials and is now being prepped for Phase II/III trials focused on proving efficacy
• The product administers neurosteroids across the blood-brain barrier to stop brain swelling following a head injury and is simple enough to be carried in a user’s pockets
• Odyssey formed a pharmaceutical subsidiary to help the company’s push toward product commercialization, and recently announced the expansion of the subsidiary’s executive team to add needed experience

Within the medical community, the tide has turned for individuals treated for physical injuries whose correlate mental deficits were previously largely undetected, undiagnosed, and untreated. Traumatic brain injuries resulting from causes as diverse as playing sports to dealing with explosives are increasingly being recognized as a health hazard that can have serious, though often unrecognized, long-term effects. Nevada-based medical technology solutions innovator Odyssey Health (OTC: ODYY) is helping to lead the search for pharmaceutical solutions for brain injuries that may remain hidden while more apparent bodily wounds are being treated, and recent additions to its executive team demonstrate the company’s expectations of commercializing its much needed products. Odyssey Health’s focus on developing and testing drug candidates to combat conditions with unmet needs has resulted in products such as a device to suck out a foreign obstruction in a choking victim’s throat, and a new solution for detecting heart disease in its early stages. But the company’s flagship development relates to marketable responses to central nervous system ailments, including the highly fatal childhood disease Niemann-Pick type C Disorder, nerve gas exposure and, most notably, brain concussions. In October, Odyssey announced the formation of its subsidiary Odyssey Neuropharma, Inc. — a wholly owned pharmaceutical company focused on the development of Odyssey’s neurosteroid solutions for treating these disorders, using its unique intranasal delivery device coupled with its powdered formulations to allow drugs to be delivered more directly and timely to the brain (https://ibn.fm/NEgom). The formation of Odyssey Neuropharma followed Odyssey’s completion of Phase I clinical testing for the safety of its drug to treat concussion, using its portable, breath-powered device that administers neurosteroidsinto the nasal cavity where receptors can transport them into the central nervous system bypassing the often stubborn blood-brain barrier. The trials found the drug candidate to be well tolerated in human subjects and their data is being communicated to the U.S. Food and Drug Administration (“FDA”) amid plans for a Phase II/III trial that aims to establish the drug’s effectiveness. In the meantime, the company’s executive team expansion includes introducing Odyssey Neuropharma’s new Chief Commercial Officer Erik Emerson and Chief Operating Officer Greg Gironda, whose experience is expected to help Odyssey with the drive toward market readiness. “The opportunity to impact the lives of our military, elderly, children, and athletes was something that one can only hope for in our careers,” Emerson stated in a company news release (https://ibn.fm/kbk7e). “Mild traumatic brain injury and the subsequent long-term effects are a true urgency. Joining the team at this critical juncture to lead our conversion of strong early science, to potential patient availability is unique.” For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetes
• The company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetes
• Lexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study on the potential treatment of hypertension
• So far, CBD has shown some ability to reduce the incidence of diabetes in mice, and Lexaria looks to build on these findings and  investigate DehydraTECH’s overall effectiveness for the potential treatment of the disease among human patients
• DIAB-A22-1 marks a notable milestone for Lexaria and is a testament to the company’s commitment to advancing its efforts to address unmet patient needs and create shareholder value

In November 2021, Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs, announced its plans for several new and ongoing research and development (“R&D”) programs on its patented DehydraTECH(TM) technology for the 2022 calendar year. The study areas included hormone replacement, dementia, rheumatoid disease, and diabetes (https://ibn.fm/yoOng). On November 8, 2022, Lexaria announced that the study program, DIAB-A22-1 began on schedule, making it the company’s first-ever study to investigate whether its DehydraTECH-processed cannabidiol (“CBD”) may potentially have therapeutic utility against diabetes (https://ibn.fm/IH3Ul). This study preceded Lexaria’s first-ever study on DehydraTECH-CBD’s potential for the treatment of dementia, which began one week later and follows the successful HYPER-H21-4 clinical study on the potential treatment of hypertension. According to the Centers for Disease Control (“CDC”), at least 37.3 million people in the United States have diabetes, representing 11.3% of the population (https://ibn.fm/vCk9i). The condition accounts for 31 out of every 100,000 deaths in the country, making it the 7th largest cause of death in the United States. In 2021, it accounted for over 100,00 deaths for the second consecutive year, spurring a call for a federal mobilization as seen before with the fight against HIV/AIDS (https://ibn.fm/mU6OO). Lexaria is optimistic that its DehydraTECH-CBD will yield notable results from this study, especially having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study (https://ibn.fm/bfWzg). There is a strong connection between heart disease, hypertension, and diabetes, with hypertension proving to be as frequent in people with diabetes and hypertensive patients being at greater risk of developing diabetes. So far, CBD has shown some ability to reduce the incidence of diabetes in mice, with the study yielding a significant decrease in pancreatic islets production of destructive insulitis and inflammatory cytokine production (https://ibn.fm/RVtmE). Lexaria looks to build on these findings and investigate whether its patented DehydraTECH-CBD may potentially have therapeutic utility against diabetes. DIAB-A22-1 marks a notable milestone for Lexaria, even as the company aims for late 2022/early 2023 for an Investigational New Drug (“IND”) application with the United States Food and Drug Administration (“FDA”) for DehydraTECH-CBD for the treatment of hypertension. It is also a testament to the company’s commitment to advancing its studies, addressing unmet patient needs, and creating shareholder value. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• RNG is considered carbon-neutral because it is derived from organic sources that produce methane emissions while decaying
• EverGen is developing Canadian RNG infrastructure with projects in British Columbia, Alberta, and Ontario
• EverGen’s expansion projects backed by Canada’s highly regulated energy sector, supported with long-term contracted revenue agreements

According to the United Nations, the future of clean energy depends on fuel sources that are economical and reliable while minimizing carbon emissions (https://ibn.fm/NSl40). Sources with a minimal or zero carbon footprint like liquified natural gas (“LNG”), solar panels, and wind turbines are viable options, however renewable natural gas (“RNG”) provides a stronger impact by removing carbon from the atmosphere. EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) is dedicated to a net-zero future that leverages renewable energy sources like RNG. The company leads RNG adoption efforts across Canada by acquiring, developing, building, and operating a portfolio of RNG and related waste-to-energy projects while developing a domestic RNG platform. RNG is considered carbon-negative because it is derived from organic sources that otherwise would decay and produce methane emissions. According to the Southern California Gas Company, RNG sourced from landfill-diverted food and green waste can provide a 125 percent reduction in greenhouse gas emissions (https://ibn.fm/XR1Kc). Further, replacing traditional vehicle fuel with RNG sourced from dairy manure can reduce greenhouse gas emissions by 400 percent, according to the utility company. EverGen is committed to expanding RNG infrastructure across Canada by investing in projects in British Columbia, Alberta, and Ontario. The company recently broke ground at its West coast Fraser Valley Biogas RNG expansion project with the goal of doubling RNG production volumes to approximately 160,000 GJ of RNG per year (https://ibn.fm/phvYB). Across the country in Ontario, the company recently acquired a 50 percent interest in Project Radius, which includes three RNG projects collectively capable of producing approximately 1.7 million GJ of RNG per year (https://ibn.fm/PVHxE). “EverGen will deliver on our platform expansion commitments with the potential to exceed 1,000,000 GJ of RNG production annually,” said Chase Edgelow, CEO of EverGen. “Ontario has an abundant amount of excess organic feedstock, and as a leader in the RNG industry, EverGen can develop the sustainable infrastructure that contributes to carbon-negative energy production and the greening of the province.” EverGen’s expansion projects are backed by Canada’s highly regulated energy sector. With the support of long-term contracted revenue agreements, the company can invest in its RNG network through a guaranteed pricing mechanism. “This is different from the US model, which is reliant on carbon credits which have a pricing mechanism that can be difficult to predict,” said Edgelow in a recent interview (https://ibn.fm/ixLJi). “What’s unique about this landscape and industry in Canada comes from what we see as a really strong tailwind for our business:  the strength of the Canadian regulated gas utilities in terms of providing long-term offtake agreements for energy derived from these RNG projects.” Based in Vancouver, British Columbia, EverGen is an established independent renewable energy producer committed to developing Canada’s RNG infrastructure. With projects located across the country, the company is emerging as a leader committed to powering a sustainable, net-zero future based on renewable energy sources. For more information, visit the company’s website at www.EverGenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

DE&I leaders, executives, and professionals from the pharma, biotech, healthcare, and allied industries, are invited to the 2nd Advancing Diversity Equity & Inclusion (“ADEI”) In Pharma and Healthcare Summit. This online live-streaming event will be held on December 8-9, 2022. The agenda will guide you to move from awareness towards advocacy and action, as you build a culture of representation and inclusion for success in the workplace and clinical trial management. Professionals and industry experts from the medical realm gather on this forum to discuss and explore ways to attain success and improve the patient’s overall experience. This live-streaming event is attended by dignitaries and medical professionals from all over the world. They share valuable insights, get the know-how of trending healthcare issues, and analyze strategies for improved drug R&D, disease awareness, and clinical trial outcomes. The event is hosted by Dynamic Global Events (“DGE”), a life science leader in organizing b2b events. The global event company strives to meet the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries. Topics being covered at the summit include:

• Build workplace cultures that support different types of people, including LGBTQ
• Work towards the inclusion of disability and neurodiversity in the workplace
• Ensure better DE&I in clinical trials and drug development
• Discuss the best yardstick to measure the scope and durability of change
• Implement a recruiting strategy that aligns with your organization’s goals
• Explore the hurdles of incorporating DE&I in medical research and publishing
• What is the status of ERGs/BRGs in driving a culture of inclusion?
• Discuss the importance of creating a sense of belonging to the different facets of the society
• Initiate employee well-being programs that protect your initiatives and gains

This summit strongly emphasizes the need for inclusivity, belonging, and equality, and demonstrates how these factors positively impact drug R&D, disease awareness, and clinical trial outcomes. There will also be a highlight case study where Pfizer will share insights on the five-point strategy the organization implemented to successfully close the gender gap and reinforce equitable gender distribution. To learn more, please visit https://ibn.fm/pdC20.

• FuelPositive Corp. is a Canadian developer of clean energy solutions, focusing on an on-site system for producing hydrogen-dense green ammonia
• The company’s modular system can produce 300 kg per day (500 liters per day) of liquid anhydrous carbon-free ammonia — the amount needed to fertilize a 2,000-acre farm
• The system’s ability to grant end users greater energy independence as a climate-friendly resource is filling a market need at an opportune time as industries struggle to manage supply chain challenges created by COVID and the ongoing Russia-Ukraine war
• The module is being tested in a pilot project by Canadian farmers and recently became available for pre-sale orders

Clean energy technology developer FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is proving itself as a thought leader and innovator of climate-friendly farming solutions vital to global economies at a time when conflicts and supply chain interruptions are stressing needed resource markets. FuelPositive’s onsite, containerized, modular system for producing green, hydrogen-dense ammonia is designed to help the fertilizer-dependent agricultural industry and other end users who may want to produce ammonia or hydrogen fuel locally. The war in Ukraine has highlighted for many the need to ensure energy and agricultural independence because of the war’s disruptions of commodities supply chains for international product shipments that normally originate not only in Ukraine but Russia as well (https://ibn.fm/ZoX5I). Nancy Qian, a co-director of Northwestern University’s Global Poverty Research Lab and the Founding Director of China Econ Lab, noted in a recent editorial for Project Syndicate that Western nations are vulnerable to agricultural export problems that exceed the measure of the war’s disruptions. Those vulnerable nations, including the United States, she argued, would do well to increase production and reserves to mitigate the impact of any disruptions both for the sake of political maneuvering and to help stave off mass starvation in economically poorer countries (https://ibn.fm/ro7Di). “The global food system urgently needs to become more resilient for political and humanitarian reasons,” Qian stated. FuelPositive’s system can produce 300 kg per day (500 liters per day) of liquid anhydrous carbon-free ammonia, a hydrogen-dense resource that FuelPositive describes as the approximate amount needed for a 2,000-acre farm’s fertilizer needs. The modular model allows for additional systems to be added on for larger farms. Because the units are portable, fitting inside standard shipping containers, they can provide users’ needs onsite and reduce concerns about the vagaries of supply chain fulfillment. In August, the units became available for pre-sale for interested farmers. In Manitoba, Canadian farmers Tracy and Curtis Hiebert are preparing to use the modular system in the company’s first demonstration pilot project to evaluate its real-world performance over a one-year period. “The FuelPositive system will give us stability. That’s what we like about it. It’s stabilizing the supply and stabilizing the price,” Curtis Hiebert stated (https://ibn.fm/dSDz7). The initial base system price will be CA$950,000, although individual farm conditions may cause variability in the actual price, the company states. FuelPositive also expects that customers can lower their cost to acquire and operate the system by using government clean tech adoption programs. Carbon credits and tax incentives will further offset costs for its customers. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• The presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as a platform for development of therapeutics addressing diseases with large unmet medical needs and attractive commercial opportunities
• BiondVax’s lead NanoAb candidate, an inhaled COVID-19 treatment, exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies
• Development of additional NanoAbs, targeting psoriasis, asthma, psoriatic arthritis and wet macular degeneration is underway via a strategic collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen (“UMG”), both in Germany

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases, recently presented at Recent Advances in Fermentation Technology (“RAFT”) 14, a conference of the Society for Industrial Microbiology and Biotechnology (“SIMB”), which took place in Orlando, Florida. RAFT provides a platform for academic and industrial scientists to discuss the latest developments in fermentation technology. BiondVax’s Head of Technical R&D, Dr. Dalit Weinstein Fischer, presented the company’s Nano-sized solution for a massive challenge: NanoAbs as a platform for COVID-19, asthma, and psoriasis therapies at the Caribe Royale Orlando on November 8, 2022 (https://ibn.fm/ziT4B).

The RAFT presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nano-sized NanoAbs (aka VHH-antibodies and nanobodies). NanoAbs are a “bio-better” category of monoclonal antibodies (“mAbs”) providing several key advantages vs. currently available mAb therapies. These advantages include speed of discovery and production (important for newly emerging infectious diseases), smaller molecule (which suggests a better safety profile with fewer side effects), lower cost of production, greater thermostability (usually translates to longer shelf life), better ability to sustain shear forces (which allows for various routes of administration such as inhalation), much higher affinity to their molecular target (which could translate to lower required dose and possibly better efficacy at a given dose), and potentially enhanced patient convenience (e,g, self-administered inhalation at home, and lower adverse effects). The company’s lead NanoAb candidate for treating COVID-19 exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies.

BiondVax is uniquely positioned to advance nano-sized antibody innovation from R&D through commercialization via top-tier pharma leadership, extensive drug development expertise, in-house GMP biologics production facility, and collaboration with Max Planck and UMG.

BiondVax is developing additional NanoAbs to address diseases with large unmet medical needs and attractive commercial opportunities, likely beginning with psoriasis and asthma. Psoriasis is an autoimmune inflammatory disorder that results in the overproduction of skin cells, leading to an itchy, red skin condition that presents with inflammation, lesions, and plaque formation.

The psoriasis treatment market was valued at $24.33 billion globally in 2021 and is projected to grow from $26.37 billion in 2022 to $47.24 billion by 2029, at a CAGR of 8.7% during the forecast period. According to the National Psoriasis Foundation (“NPF”) estimations, around 125 million patients globally suffered from psoriasis in 2020, with a prevalence between 1.5% and 5% in developed countries (https://ibn.fm/ciyBo).

BiondVax’s drug development expertise stems in part from its past experience with the development of a novel universal flu vaccine licensed from the Weizmann Institute of Science Lab of Professor Ruth Arnon, known for being the co-developer of Copaxone, Teva Pharmaceuticals’ block buster multiple sclerosis drug. During development of its prior vaccine candidate, BiondVax conducted seven phase 1/2 and phase 2 clinical trials in Israel, Europe, and the USA, and a seven-country pivotal Phase 3 trial conducted from 2018 to 2020 that was completed on-time and on-budget.

BiondVax is a public company traded on Nasdaq with the ticker BVXV. 21% of its shares are held by the cyber security mogul Marius Nacht, the founder of the world leading cyber security company CheckPoint (NASDAQ: CHKP).

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• While governmental leaders continue to work toward measurable climate progress, U.S.-based Correlate Infrastructure Partners Inc. is helping corporate clients attain ESG successes sought by investors
• The company recently reported that completion of construction milestones in contracted projects has netted it an 877 percent jump in revenues from Q2 to Q3, amounting to a 15,024 percent increase YOY
• CIPI’s efforts include helping clients achieve significant yet affordable change in their facilities’ utilities usage through improvements to mechanical, electrical, and plumbing processes, the addition of solar upgrades, water optimization, and other strategic measures

Nearly a decade has passed since world leaders agreed to pursue pollution reduction strategies to keep global temperature increases from peaking at more than 1.5 degrees Celsius above the planet-wide temperature peaks recorded nearly 300 years ago, and many climate policy makers who gathered this month for the latest United Nations-sponsored Conference of the Parties (“COP27”) climate change conference expressed concerns that not enough has been done to adhere to the agreement (https://ibn.fm/q0HDx). While U.S. President Joe Biden and Chinese President Xi Jinping declared Nov. 14 they would set aside disagreements over some of the countries’ policies enough to work together on fighting climate change, protecting global health and safeguarding access to food, many industries are also doing their part to show environmental, social and governance (“ESG”) responsibility in order to appeal to investors (https://ibn.fm/MK8lv). Correlate Infrastructure Partners (OTCQB: CIPI), a U.S. company that advises the commercial real estate industry (companies that develop and rent out commercial building properties) on potential ESG improvements and financing opportunities to make those improvements both workable and economical, is demonstrating its own success through a major jump in revenues from its operations. The company reported Nov. 14 that its quarterly income had grown 877 percent over the previous quarter from $236,690 to $2,312,577, due largely to completion of construction milestones in contracted projects. Year-over-year, Correlate Infrastructure’s revenues grew by nearly 15,024 percent. “We continue to make smart choices to optimize our organic project delivery based on a dynamic 2022 regulatory and supply chain landscape,” CEO Todd Michaels stated in the company’s Nov. 14 announcement (https://ibn.fm/1Jbdr). “The Inflation Reduction Act enacted in late August (by the federal government) provided new tax incentives that reduce costs for clients and/or elevate returns to investors; this led to larger contract sizes with redesigns to domestic content. While this meant delaying some project starts, it will be a big net gain, and will open new markets for us in 2023.” CIPI has another $16.2 million in unrecognized revenues in the pipeline for projects currently being installed at customer locations. All in all, the company currently has project opportunities valued at up to $194 million when projects in development are taken into consideration to include agreements that have been awarded but have not yet reached the executed contract stage. The figures indicate a measure of CIPI’s success in delivering advisory assistance on acquisitions and project development for environmentally friendly solutions, paired with infrastructure and financing resources. The company’s subsidiaries, Correlate, Inc. and Loyal Enterprises LLC (dba Solar Site Design), analyze utilities usage and provide data-driven recommendations for improvements to HVAC, mechanical, electrical and plumbing processes, the addition of solar upgrades, water optimization and antimicrobial airflow, the strategic procurement of energy sources, vehicle electrification and master controls that provide intelligent oversight of any retrofits. The availability of government subsidies and the discovery of other financial incentives helps round out the benefits the companies provide. Correlate’s growth points to the rising demand for its expertise. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• The online advertising ecosystem is transforming as governments worldwide ramp up regulations to rein in collection of consumers’ personal data
• Google’s Privacy Sandbox works toward the end of third-party cookies in Chrome, giving rise to a whole new privacy-compliant identity ecosystem
• As a company driven by the evolution of data privacy and its impact on consumers and companies, Reklaim appears well-positioned to capitalize on emerging market opportunities amid a paradigm shift happening with new privacy laws

User privacy is taking the online space by storm as consumers become increasingly conscious about how their online data is harvested and used. As a result, the online advertising architecture is about to transform, and companies like Reklaim (TSX.V: MYID) (OTCQB: MYIDF) appear ready to seize the market opportunity that emerges amid intensified regulatory and consumer data protection scrutiny.

As consumers increase their presence in the digital space, the data they generate presents both an opportunity for brands to enhance their engagement with target audiences and a responsibility to keep that data safe. In a post-Cambridge Analytica world – a high-profile case exposing how Facebook used personal data from millions of profiles without their consent – consumers are increasingly wary about what data they share and with whom. According to Pew Research, an overwhelming majority of them – 72% – think their online activity is constantly tracked (https://ibn.fm/6AlKv).

Consumers seem to be constantly reminded that their heightened distrust may not be all that unwarranted as the lineup of companies coming into the spotlight due to their data protection failures expands. Most recently, it was Chegg Inc., an EdTech company providing services for high school and college students.

In its commitment to better protect Americans’ privacy and clamp down on businesses that collect personal information without consumers’ complete understanding, The Federal Trade Commission recently announced that it is taking action against Chegg Inc. for its lenient data security practices that exposed personal information about millions of its customers and employees, including, email addresses, passwords and Social Security numbers (https://ibn.fm/GE3H4).

Still, businesses and their digital marketing rely on collecting data on the online behavior of their target audiences. As a result, the sector has been on a winning streak (with revenue exploding at a record 35.4% in 2021) and is gearing up for another watershed year (https://ibn.fm/eOA4i). Without the free rein to collect consumers’ data, digital advertising needs a paradigm shift aligned with the new world in which consumers, regulators and technology companies require improved data privacy standards, which means the end of third-party cookies.

Previously, businesses could track consumers as they moved across multiple platforms and apps, collecting troves of information about their browsing habits. For example, Facebook aggregates a vast amount of data its users share about themselves as they engage with content and their connections. This information was then distributed to businesses that advertise on the platform so that they could deliver more relevant offers to their target audiences. With a bit of tech help called cookies – a piece of code stored in users’ browsers that collects data about them as they visit and interact with the web – businesses were able to learn about consumers’ online behavior. However, as it turns out, not all cookies are created equal. First-party cookies are limited to a single website, platform or app. Third-party cookies are designed to track users across the online space, allowing third parties to follow the entirety of a user’s internet activity and their online behavior and habits across practically the entire digital space.

It’s the third-party cookies that the latest privacy regulation aims to crack down on, and major tech companies play an essential role in these privacy-driven efforts. To protect users’ online privacy and help companies build thriving digital businesses, Google created Privacy Sandbox, a collaborative effort of the web community to develop privacy-first alternatives to third-party cookies. “Stage 1” of the transition will begin in late 2022, while support for third-party cookies is expected to be removed from Google’s Chrome browser in late 2023.

In a cookie-less reality, brands need to rethink their marketing approach and build advertising strategies around alternatives to third-party cookies. The new strategy relies on migration toward a zero- and first-party data approach, which presents a significant opportunity for innovation that allows businesses to mitigate regulatory risk while protecting and growing marketing revenue. This can improve customer satisfaction and enable marketers to make smarter decisions by reducing data silos (https://ibn.fm/mhInK).

Reklaim intends to step in as a company driven by the evolution of privacy and how it impacts consumers and businesses. Founded in 2018 and with headquarters in New York and offices in Toronto, Reklaim offers a privacy-compliant identity ecosystem. The company is focused on selling compliant, zero-party data to Fortune 500 brands and agencies that buy advertising, as well as platforms and data companies that sell data. Reklaim not only helps clients stay compliant amid the rapidly changing privacy market but also gives consumers visibility regarding how their data is collected and compensates them for its use. Positioned for the cookie-less future that is fast approaching, Reklaim seeks to empower consumers to take back control of their digital data that has been collected and sold for years without their explicit consent.

For more information, visit the company’s website at www.ReklaimYours.com.

NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• Lexaria Bioscience recently received Independent Review Board approval for its upcoming human clinical nicotine study, NIC-H22-1, and expects to begin dosing soon
• The company hopes to evidence that processing purified nicotine with its patented DehydraTECH(TM) drug delivery technology leads to better oral-tissue absorption and reduced negative experiences compared to leading brands currently available on the market, On! and Zyn
• Last year, Lexaria conducted an animal study evaluating oral nicotine absorption, NIC-A21-1, in which it evidenced that its DehydraTECH technology was ten to twenty times faster in delivering comparable levels of nicotine into the bloodstream than the peak of the concentration-matched controls

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced it had received Independent Review Board (“IRB”) approval for its planned human clinical nicotine study, NIC-H22-1 (https://ibn.fm/ONgsR). According to U.S. Food and Drug Administration (“FDA”) regulations, the receipt of the IRB approval by Lexaria means the company has taken the necessary steps to protect the rights and welfare of humans participating as subjects in its upcoming human study (https://ibn.fm/CQIHx). The pharmacokinetic (“PK”) randomized, double-blinded, cross-over study will comprise 36 human subjects who are current cigarette smokers. Each subject will visit the laboratory, where they will be dosed three times over a period of weeks. Only one of three nicotine pouch brands – DehydraTECH(TM)-nicotine, On! brand manufactured by Altria, or Zyn brand manufactured by Swedish Match – will be administered during each visit. Subjective and objective evaluations will then follow. Through predetermined questionnaires, which will be used for each nicotine pouch, aiding in subjective evaluation, Lexaria will seek data related to throat burn, user experience, gastrointestinal experience, and more. Additionally, blood samples taken a total of eight times per visit will help in objective evaluations associated with the quantity of nicotine in the blood at various time points. At the same time, vital signs such as respiratory rate, heart rate, blood pressure, and temperature will also be collected. “This is a human clinical study to be conducted in the United States. It uses a DehydraTECH-oral nicotine powder that we have developed… The nicotine powder we will be using is one we already tested in animals last year – we had exceptionally strong results,” said CEO Chris Bunka in an interview with Proactive (https://ibn.fm/G7Tmx). “We believe, right now, that the Lexaria oral nicotine powder is the most advanced of its kind in the world, and we are going head-to-head with two of the top three leading brands of oral nicotine powders today: those manufactured by Swedish Match as well as by Altria. So, we are really excited for the study to commence.” Last October, Lexaria announced “outstanding results” from its NIC-A21-1 study evaluating oral nicotine absorption in animals. The company revealed that DehydraTECH needed only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls. The results also showed that DehydraTECH-nicotine reached statistically significant peak blood plasma levels up to 10x higher overall than controls while still clearing from blood virtually as quickly as the controls. (https://ibn.fm/PuZTI). “We are extremely pleased with the performance of our latest DehydraTECH-2.0 nicotine oral formulations in this study,” said Chris Bunka at that time. “Our technology was ten to twenty times faster in delivering comparable levels of nicotine into the bloodstream than the peak of the concentration-matched controls and went on to far exceed their total delivery, which should provide much greater consumer satisfaction.” Following receipt of the IRB approval, Lexaria expects to begin human dosing soon, with CEO Chris Bunka hinting during the Proactive interview, published November 3, that dosing will “have been completed in the next month or two and results [released] shortly thereafter.” The company hopes to evidence that processing purified nicotine with its patented DehydraTECH drug delivery technology leads to better oral-tissue absorption and reduced negative experiences compared to the brands currently available on the market. Ultimately, and upon undergoing necessary evaluations, Lexaria hopes to license its technology in the oral pouch product category to offer better nicotine satiety and effectiveness, with the goal of one day rendering cigarette smoking and vaping as obsolete. This would potentially help stop the devastating consequences of cigarette smoking – the practice annually claims more than 480,000 lives in the United States (https://ibn.fm/kVjtw) and over 8 million lives globally (https://ibn.fm/9F3jG). Smoking is also linked to such maladies as cancer (trachea, lung, and bronchus), bronchitis, and coronary heart disease. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• EverGen commenced construction at its Core RNG Expansion Project at Fraser Valley Biogas; project is advancing on schedule and on budget with expected completion in Q1 2023
• Expansion is estimated to double FVB’s capacity to ~160,000 GJ of RNG per year; coupled with new long-term offtake agreement executed in current robust RNG market, it is expected to provide significant boost to company’s revenues and EBITDA
• As Canada’s early mover, EverGen seeks to consolidate assets across the country and leverage its expertise in designing and optimizing resilient facilities; with team that has seen more than a hundred RNG projects, company boasts a distinctive competitive advantage

EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), Canada’s Renewable Natural Gas infrastructure platform that helps the fight against climate change and transition to a sustainable future, has announced that the company started construction work at its Core RNG Expansion Project at Fraser Valley Biogas –the Abbotsford, BC facility that combines anaerobic digestion and biogas upgrading to produce RNG. The project broke ground in Q3 2022 and is expected to complete in Q1 2023, when the facility will ramp up RNG production to the expanded capacity (https://ibn.fm/BgUzG). “We are proud of what our team has been able to achieve at FVB to date and pleased to see the project advancing on schedule and on budget,” said Chase Edgelow, CEO of EverGen. “All major mechanical equipment is on track for delivery and costs are within our C$13M-C$15M capital budget. These developments, coupled with the execution of a new long-term offtake agreement in a significantly stronger RNG market, will provide a substantial lift to our revenues and EBITDA.” The initial work is focused on an additional anaerobic digestor and upgrades of the existing feedstock processing system with a view to increase the facility’s production capacity. Upon the completion of this expansion project, the new RNG production volumes are expected to double the capacity of the facility to produce ~160,000 GJ of RNG per year. Established in 2011, Fraser Valley Biogas is Canada’s first agricultural digester to produce renewable natural gas. The RNG generated through this project that EverGen acquired in early 2021 is part of FortisBC’s program to supply renewable gas to homes and businesses. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced as part of the process (https://ibn.fm/BC9Z8). As an established independent renewable energy producer focused on acquiring, developing, owning and operating a portfolio of RNG waste-to-energy, and related infrastructure projects, EverGen is confident that it is heading to a catalyst-rich quarter. “We’re one of the first movers in Canada in terms of consolidating assets across the country. I think when we look at the RNG space today, it’s very similar to what the wind and solar space looked like, maybe ten or fifteen years ago. There’s a number of single project owners that are smaller businesses with greenfield projects. There are some existing assets that probably need more capital to be invested. We’ve taken an approach that we want to be a developer developing new projects from scratch, an owner and an operator of these facilities and to have a platform to be able to be in multiple provinces to share resources. That’s been our strategy and we’ve been effectively growing at a rapid pace with acquisitions that we’ve done in BC. This year we’ve done additional acquisitions in Alberta. We’ve got a significant development project, project Radius, the facilities in Ontario that give us our next leg of growth. We are looking at other provinces for other development projects that sit within our pipeline”, said Chase Edgelow describing the company’s growth plans (https://ibn.fm/ErAn8). “It’s about having technical expertise in the RNG space, so having the personnel that understands how to optimize these facilities, how to ensure you’re designing a facility that will be resilient. Our team has seen over a hundred projects in the space and that really helps us have an advantage with some of the smaller asset owners to be able to bring these projects into our portfolio to share the upside with them and to be able to continue to develop and grow across the country,” he concluded as he described the competitive advantage of the company that seeks to position itself as a leader in the RNG market. For more information, visit the company’s website at www.EverGenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF